Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047

Trial Profile

Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Neurogenic bladder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Apr 2017 Planned End Date changed from 26 Dec 2019 to 1 Jun 2020.
    • 07 Apr 2017 Planned primary completion date changed from 26 Nov 2019 to 1 May 2020.
    • 15 Jul 2016 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top